The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.
about
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human geneticsCeliac disease: prevalence, diagnosis, pathogenesis and treatmentType 1 diabetes mellitus and gluten induced disordersNon-dietary forms of treatment for adult celiac diseaseTight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancerThe potential utility of tight junction regulation in celiac disease: focus on larazotide acetateTherapeutic approaches for celiac diseaseNon-dietary methods in the treatment of celiac diseaseNon-systemic drugs: a critical reviewThe role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel diseaseNovel therapeutic/integrative approaches for celiac disease and dermatitis herpetiformisCurrent and emerging therapy for celiac diseaseProperties of Gluten Intolerance: Gluten Structure, Evolution, Pathogenicity and Detoxification CapabilitiesLeaky gut and autoimmune diseasesIntestinal permeability and its regulation by zonulin: diagnostic and therapeutic implicationsParallels between pathogens and gluten peptides in celiac sprueCeliac disease in Middle Eastern and North African countries: a new burden?Identification of gliadin-binding peptides by phage display.Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology.Celiac disease and pediatric type 1 diabetes: diagnostic and treatment dilemmas.Novel therapies for coeliac diseaseReview article: coeliac disease, new approaches to therapy.Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat.Zonulin, regulation of tight junctions, and autoimmune diseases.Pathophysiology of celiac diseaseThe present and the future in the diagnosis and management of celiac disease.Prevention measures and exploratory pharmacological treatments of celiac disease.Update on celiac disease - etiology, differential diagnosis, drug targets, and management advances.A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challengeLarazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.The management of refractory coeliac disease.Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac diseaseCeliac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms.Celiac disease: risk assessment, diagnosis, and monitoring.Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trialsLarazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac diseaseIncreased bacterial translocation in gluten-sensitive mice is independent of small intestinal paracellular permeability defectTNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway.Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall
P2860
Q21131205-991F6C0B-6FDE-4723-80A9-650FCA055975Q22305490-535F0AF1-98B7-43DA-A577-3D79165E27BCQ24562995-326A8D4C-2EA5-4965-BEE7-E17FD2151788Q24602271-FDA7976D-AE4D-4438-808F-9D23AFFC43AEQ26752750-2E5AA39A-8F96-4251-AED6-75FA9B2A0DA7Q26771888-4F589330-25A5-47A1-A612-12FD8B919156Q26825413-20076588-DA5D-41F7-806C-35D16B542631Q26863359-97DD42F8-E0D8-4D9A-BEAA-EBDEE855ADD1Q26863371-36E86DBF-1B5F-4BCE-A2B3-5355B2DF514EQ27007776-EDB1DCEE-9903-4607-A73F-C487CAA1DE57Q27010008-622BF3B4-0B17-4FFD-B470-D1A96CE860FAQ27014843-D09915CC-1F57-4B4C-978D-72A97F97FEADQ28072666-0E861E69-9F4E-4651-BC80-E2F4E22173A3Q28253767-809C6AF0-3EC8-44FF-A13E-93220DD83115Q28273316-09CF537C-2FCC-4F22-A363-1FD2F7254EBFQ33329537-A2CB219F-3CA5-481E-9461-E38188305BADQ33756236-D56D6D9E-A5E2-4330-8832-D172D06DCAF4Q33823074-6A0A3757-38F3-492E-B072-572BD4A02231Q33956436-2F0A9DF0-259A-4133-B165-325CCAC4B84EQ34002003-96F9E29D-2D9B-4E4A-8C28-98D0D73877CFQ34170574-8C703F67-33B2-4ED3-9374-2B9ECB448409Q34253519-820FFEEF-D7AD-4366-AFF7-D5F0B96AB220Q34283907-6636674A-760E-4D9F-A8C2-D37FC7471C92Q34283930-15886351-01F2-42EE-8663-3658C28E72A8Q34307239-3F3038BF-BCA3-4938-9F0E-B7A7BA7B75D5Q34444067-67794B5A-EEE6-45B5-9EC5-D80DC3944572Q34623902-78E63CC1-7162-48EE-B446-328DEE1F043EQ34635029-29C5A2BC-545E-4259-B86E-0A4E456614E4Q34640687-976DCD01-7D42-4B9E-9D7F-F13E12FC59F2Q34645550-7419FA50-0F23-4116-8490-4953526D13ADQ34650083-A7D134F7-3413-4D10-8D17-6326C74A0C76Q34739387-1A0E5ADC-CD9B-4339-8A96-E86E28D4254FQ34809320-8DC8CD06-F48E-4B38-A409-C50106CDFB3DQ34831592-DEBA3542-3BC1-4327-95B1-FC0CDA0054C3Q35580144-D3A759E7-0857-4780-B259-678B2F77EBDCQ35655989-66261BBB-71AC-41F4-9133-F4A6297FCFD3Q35857457-D833FA1D-CCED-49ED-8AD1-2A7CE21C4D84Q36426072-81D60806-E543-4E9D-BE59-A8A834ABA7B2Q36885702-16ED94B4-EE5A-4DB0-A655-39E8009452CCQ36943034-12326448-3669-43E6-999E-5E8784C67FBD
P2860
The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@ast
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@en
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@nl
type
label
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@ast
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@en
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@nl
prefLabel
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@ast
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@en
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@nl
P2093
P1476
The safety, tolerance, pharmac ...... cts: a proof of concept study.
@en
P2093
Arrieta MC
Lammers KM
Meddings JB
Paterson BM
P304
P356
10.1111/J.1365-2036.2007.03413.X
P407
P577
2007-09-01T00:00:00Z